`
`Lqin Plnmaceuicds, hc.
`
`"Imus ‘men 3
`E
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`
`F
`.
`.
`
`.
`
`me’
`.
`.
`.
`.
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`. .. .
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`. ..
`
`Our mission is to become a transnational pharmaceutical company
`through the development and introduction of a wide portfolio of branded
`.. . ‘I
`I
`.
`“_
`1‘
`
`
`
`Who We Are
`
`
`
`
`
`
`
`is the U.S. wholly owned subsidiary of Lupin
`Lupin Pharmaceuticals, Inc.
`Limited, which is among the top five phannaceutical companies in India.
`Through our sales and marketing headquarters in Baltimore, MD, Lupin
`Phannaoeuticals, Inc. is dedicated to delivering high—qua|ity, branded and
`generic medications trusted by healthcare professionals and patients
`across geographies.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`is strongly research
`India,
`Lupin Limited, headquartered in Mumbai,
`focused. It has a program for developing New Chemical Entities. The
`
`company has a state-of-the-art R&D center in Pune and is a leading global
`
`player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs
`(ACE-inhibitors and cholesterol
`reducing agents) and has a notable
`
`presence in the areas of diabetes, anti-inflammatory and respiratory
`therapy.
`
`We are building on our parent company's strengths of vertical integration
`in discovery research, process chemistry, active pharmaceutical ingredient
`production,
`formulation development
`and regulatory filings. Lupin
`Pharmaceuticals, Inc. is committed to achieving its vision and mission of
`becoming an innovation led transnational phannaceutical company.
`
`Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc. says "founded on the
`strengths of our parent company Lupin Limited, Lupin Phannaceuticals,
`Inc. intends to bring a portfolio of generics as well as branded products to
`the US market.“
`
`For the financial year ended 31st March 2015, Lupin's Consolidated
`turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion)
`and Rs. 24,032 million (USD 393 million) respectively.Please visit
`http://www.lupinwor|d.com for more infonnation.
`
`A
`
`L
`
`Copyright © 2010, Lupin Pharmaceuticals, Inc., All Rights Reserved.
`
`1’38° 1 9‘ 1
`IIlp1Iwww.Iqlr|ilImaoe|lIais.oanIzixntflrn
`
`SENJU EXHIBIT 2263
`LUPIN v. SENJU
`IPR20l5-01100
`
`1I1